Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

Completion occurs 5 months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, May 12 /PRNewswire-FirstCall/ - Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug. Our clinical team and our collaborators at the Cleveland Clinic will now spend the next few months assessing the study results to best plan for upcoming trials. The swift completion of the ASSERT study further allows us to make better assessments in identifying optimal dosing regimens moving forward," explained Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey continued, "Earlier studies have indicated that the drug worked best in those subjects with low HDL, therefore we will further assess if RVX-208 has a targeted effect in this high risk cardiovascular disease population. The rapid enrollment and dosing success for this trial was in large part due to having one organized Internal Review Board (IRB) for all 40 sites involved in the trial."

The ASSERT trial is a randomized, double-blind, placebo-controlled, multi-centered US study for 13 weeks of administration of RVX-208, which has enrolled 299 patients with stable coronary artery disease for a period of 13 weeks. The primary endpoint of the study is to determine if RVX-208 will produce an increase in plasma Apolipoprotein A-I (ApoA-I) levels compared to placebo group after three months of dosing. Other objectives are to examine the safety and tolerability of RVX-208 and to com
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... New open ... journal serving the international surgical community ... scientific, technical, and medical information products and services, today ... of Surgery Open ( IJS Open ), ... surgery. This peer-reviewed, online-only journal will make significant contributions ...
(Date:8/4/2015)... Aug. 4, 2015  Natera, Inc. (Nasdaq: NTRA ... analysis of circulating cell-free DNA, today announced that it ... 30, 2015 after the market close on August 12, ... at 1:30 p.m. PT (4:30 p.m. ET) to discuss ... Quarter 2015 Results Conference Call  Date: , Wednesday, August ...
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
(Date:8/3/2015)... Aug. 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... for the second quarter 2015 on Monday, August 10, ... Helen Torley , president and chief executive officer, will ... will release financial results for the second quarter 2015. ... the "Investors" section of Halozyme,s corporate website and a ...
Breaking Biology Technology:Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4Natera to Release Second Quarter 2015 Results on August 12, 2015 2FamilyCord Announces Acquisition of LifeLine Cryogenics 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2
... on Global List for Fifth Consecutive Year, ... GENZ ) announced today that scientists have again ... ranking the reputations of biotechnology and,pharmaceutical companies. Genzyme ... the past five years Genzyme has consistently placed ...
... ... Marketing and Sales, and James Carr Promoted To Vice ... in China -, - Details to be Presented at Investor Briefing Today at 12 p.m. Eastern ... Time -, SOUTH SAN FRANCISCO, Calif., Oct. ...
... Rutgers physicist Emil Yuzbashyan has received a Packard Foundation ... research funding for five years. This marks the first ... to a Rutgers University professor. , Yuzbashyan is among ... 50 of the nations top private and public research ...
Cached Biology Technology:Genzyme Recognized by Scientists as a Top Employer 2Genzyme Recognized by Scientists as a Top Employer 3Genzyme Recognized by Scientists as a Top Employer 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 7Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... at the National Institute of Standards and Technology (NIST) ... refrigerant fluids with low "global warming potential" (GWP) ... many decades as well as other desirable performance ... most extensive systematic search for a new class of ...
... /PRNewswire-iReach/ -- Global Information Inc is pleased to offer ... conferences around the world. Early Bird registration prices end ... save up to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ... 11, 2013 | San Francisco, California CHI,s ...
... pioneering wildlife ecologist Aldo Leopold was a meticulous taker of ... bench at his Sauk County shack in Depression-era Wisconsin, Leopold ... with the first pre-dawn calls of the indigo bunting or ... songs he heard, when he heard them, and details such ...
Cached Biology News:New NIST screening method identifies 1,200 candidate refrigerants to combat global warming 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4Aldo Leopold's field notes score a lost 'soundscape' 2Aldo Leopold's field notes score a lost 'soundscape' 3
... Rabbit polyclonal to JAK2 (phospho Y1007) ... applications). Antigen: ... around the phosphorylation site of tyrosine ... Entrez Gene ID: 3717 ...
... Fixation Buffer, used in conjunction with ... can be used to fix and ... staining of cytokines and other cytoplasmic ... been specially formulated for reducing non-specific ...
Harmful, Irritant, Combustible ,DEPC...
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... amino acid sequence is proprietary)(Peptide available as ... Gene ID: 55693 ...
Biology Products: